Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant in IPF with Persistent Cough
NCT02502097Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of gefapixant in cough (4 arms), sponsored by Merck & Co. Primary endpoint: Awake Objective Cough Frequency at Day 14. Started Aug 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
cough
Beyond the preview
Go deeper on NCT02502097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502097.